DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment of Cocaine Dependence With Lisdexamfetamine

Information source: University of Minnesota - Clinical and Translational Science Institute
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cocaine Dependence

Intervention: lisdexamfetamine (Drug); placebo (Drug); cognitive behavioral therapy (Behavioral)

Phase: Phase 2

Status: Completed

Sponsored by: University of Minnesota - Clinical and Translational Science Institute

Official(s) and/or principal investigator(s):
David V Herin, Ph.D., Principal Investigator, Affiliation: University of Minnesota - Clinical and Translational Science Institute

Summary

This protocol is a 2-group double-blind placebo-controlled outpatient study investigating lisdexamfetamine for treatment of cocaine dependence. The investigators plan to enroll 100 subjects in a 14-week trial. The primary objectives will determine changes in cocaine use and secondary objectives will be cocaine craving and impulsivity.

Clinical Details

Official title: Lisdexamfetamine Treatment for Cocaine Dependence

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Cocaine-positive urine results

Secondary outcome: Drug craving, impulsivity

Detailed description: This 2-group, double-blind, placebo-controlled, 14-week study (N=100) will investigate the efficacy of cognitive behavioral therapy plus lisdexamfetamine vs. placebo to treat cocaine dependence. We hypothesize that lisdexamfetamine will reduce cocaine use (primary outcome), as well as cocaine craving and impulsivity (secondary outcomes) vs. placebo.

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Eligible participants must:

1. Be treatment-seeking males or females between 18 and 65 years-of-age; 2. Understand the study procedures and provide written informed consent; 3. Be judged by the examining physician to be in generally good health with the exception of health problems related to acute drug use; 4. Meet DSM-IV criteria for cocaine-dependence. Exclusion Criteria:

- Exclusion criteria include:

1. DSM-IV diagnoses for current psychotic disorders, mood disorders (except substance-induced depression), anxiety disorders, ADHD, and other current substance dependence (except marijuana and nicotine dependence); subjects may not have physiological dependence upon alcohol requiring medical detoxification; 2. Current use of any prescription medications; 3. Females currently pregnant or nursing; 4. Current elevation of liver enzyme levels above twice normal limits; 5. Existing cardiovascular disease as determined by physician, EKG evaluation; 6. History of significant acute or chronic physical illness precluding participation; 7. History of hyperthyroidism, glaucoma, or seizures.

Locations and Contacts

Ambulatory Research Center/Fairview University Psychiatry Dept, Minneapolis, Minnesota 55454, United States
Additional Information

Starting date: July 2009
Last updated: November 12, 2013

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017